

Lana Chahine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8388445/publications.pdf>

Version: 2024-02-01

70
papers

3,029
citations

201385

27
h-index

182168

51
g-index

74
all docs

74
docs citations

74
times ranked

3784
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Mild Parkinsonian Signs, Energy Decline, and Striatal Volume in Community-Dwelling Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 800-806. | 1.7 | 2 |
| 2 | Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 76-81. | 0.8 | 3 |
| 3 | Surveying Global Availability of Parkinson's Disease Treatment. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1023-1034. | 1.5 | 2 |
| 4 | Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. <i>Acta Neuropathologica Communications</i> , 2022, 10, 21. | 2.4 | 8 |
| 5 | Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214. | 0.8 | 5 |
| 6 | Triggers and alleviating factors for fatigue in Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0245285. | 1.1 | 9 |
| 7 | Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1276-1277. | 2.2 | 2 |
| 8 | Contribution of neuropsychiatric symptoms in Parkinson's disease to different domains of caregiver burden. <i>Journal of Neurology</i> , 2021, 268, 2961-2972. | 1.8 | 10 |
| 9 | Knowledge, Responsibilities, and Peer Advice From Care Partners of Patients With Parkinson Disease Psychosis. <i>Frontiers in Neurology</i> , 2021, 12, 633645. | 1.1 | 4 |
| 10 | Use of Figurative Language by People With Parkinson Disease to Describe "Off" Periods. <i>Neurology: Clinical Practice</i> , 2021, 11, e462-e471. | 0.8 | 2 |
| 11 | The experience of care partners of patients with Parkinson's disease psychosis. <i>PLoS ONE</i> , 2021, 16, e0248968. | 1.1 | 7 |
| 12 | Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1972-1978. | 2.2 | 10 |
| 13 | Author Response: In Vivo Distribution of α -Synuclein in Multiple Tissues and Biofluids in Parkinson Disease. <i>Neurology</i> , 2021, 96, 965-967. | 1.5 | 0 |
| 14 | The Experience of OFF Periods in Parkinson's Disease: Descriptions, Triggers, and Alleviating Factors. <i>Journal of Patient-centered Research and Reviews</i> , 2021, 8, 232-238. | 0.6 | 2 |
| 15 | Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning. <i>The Lancet Digital Health</i> , 2021, 3, e555-e564. | 5.9 | 29 |
| 16 | Dopamine transporter imaging predicts clinically-defined α -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 201-212. | 1.7 | 37 |
| 17 | Diffusion Tensor Imaging of the Olfactory System in Older Adults With and Without Hyposmia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 648598. | 1.7 | 8 |
| 18 | Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80. | 4.9 | 94 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Regional Gray Matter Volume Links Rest-Activity Rhythm Fragmentation With Past Cognitive Decline. American Journal of Geriatric Psychiatry, 2020, 28, 248-251. | 0.6 | 6 |
| 20 | In vivo distribution of α -synuclein in multiple tissues and biofluids in Parkinson disease. Neurology, 2020, 95, e1267-e1284. | 1.5 | 91 |
| 21 | Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Annals of Clinical and Translational Neurology, 2020, 7, 1816-1830. | 1.7 | 23 |
| 22 | Reply to Comment on: The Most Bothersome Aspects of off Periods Reported by Individuals with Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 879-880. | 0.8 | 0 |
| 23 | The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1365-1377. | 1.5 | 114 |
| 24 | Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Movement Disorders, 2020, 35, 1999-2008. | 2.2 | 104 |
| 25 | Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. Journal of Parkinson's Disease, 2020, 10, 665-675. | 1.5 | 25 |
| 26 | Sleep and circadian rhythms in the treatment, trajectory, and prevention of neurodegenerative disease. Neurobiology of Disease, 2020, 145, 105075. | 2.1 | 1 |
| 27 | Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Annals of Neurology, 2020, 88, 574-587. | 2.8 | 55 |
| 28 | Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. Movement Disorders, 2020, 35, 1618-1625. | 2.2 | 31 |
| 29 | Understanding the Lexicon of Fatigue in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1185-1193. | 1.5 | 4 |
| 30 | The Most Bothersome Aspects of <i>Off</i> Periods Reported by Individuals with Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 284-292. | 0.8 | 11 |
| 31 | Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. Movement Disorders, 2020, 35, 833-844. | 2.2 | 48 |
| 32 | Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. Journal of Parkinson's Disease, 2020, 10, 677-691. | 1.5 | 15 |
| 33 | Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals of Clinical and Translational Neurology, 2020, 7, 449-461. | 1.7 | 44 |
| 34 | Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East. Journal of Parkinson's Disease, 2020, 10, 729-741. | 1.5 | 8 |
| 35 | Nocturnal psychosis. , 2020, , 35-45. | | 0 |
| 36 | Hyposmia and Neuroimaging Signature in Community-Dwelling Older Adults. Innovation in Aging, 2020, 4, 530-530. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Restless legs syndrome and periodic limb movements. , 2020, , 77-87. | | 0 |
| 38 | REM sleep behavior disorder in Parkinson's disease. , 2020, , 47-60. | | 0 |
| 39 | Longitudinal analyses of cerebrospinal fluid α -Synuclein in prodromal and early Parkinson's disease. Movement Disorders, 2019, 34, 1354-1364. | 2.2 | 89 |
| 40 | Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. Journal of Parkinson's Disease, 2019, 9, 665-679. | 1.5 | 15 |
| 41 | Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209. | 1.1 | 15 |
| 42 | Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder. Npj Parkinson's Disease, 2019, 5, 2. | 2.5 | 24 |
| 43 | Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. Npj Parkinson's Disease, 2019, 5, 7. | 2.5 | 40 |
| 44 | Revision of Diagnosis in Early Parkinsonism with Abnormal Dopamine Transporter Imaging. Journal of Parkinson's Disease, 2019, 9, 327-334. | 1.5 | 6 |
| 45 | Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. European Journal of Neurology, 2019, 26, 246. | 1.7 | 43 |
| 46 | Self-reported physical activity levels and clinical progression in early Parkinson's disease. Parkinsonism and Related Disorders, 2019, 61, 118-125. | 1.1 | 53 |
| 47 | Update on treatments for nonmotor symptoms of Parkinson's diseaseâ€”an evidenceâ€based medicine review. Movement Disorders, 2019, 34, 180-198. | 2.2 | 619 |
| 48 | Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Movement Disorders, 2018, 33, 771-782. | 2.2 | 136 |
| 49 | Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 78-88. | 0.9 | 85 |
| 50 | <i>APOE</i> , thought disorder, and SPAREâ€AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297. | 2.2 | 35 |
| 51 | The Parkinson's progression markers initiative (PPMI) â€ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477. | 1.7 | 330 |
| 52 | Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α -Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). Journal of Parkinson's Disease, 2018, 8, 517-527. | 1.5 | 16 |
| 53 | Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). Journal of Neuropathology and Experimental Neurology, 2018, 77, 793-802. | 0.9 | 32 |
| 54 | Cognition among individuals along a spectrum of increased risk for Parkinson's disease. PLoS ONE, 2018, 13, e0201964. | 1.1 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2017, 11, 359-368. | 0.6 | 50 |
| 56 | Treatment of Sleep Dysfunction in Parkinson's Disease. <i>Current Treatment Options in Neurology</i> , 2017, 19, 26. | 0.7 | 44 |
| 57 | Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1640-1645. | 2.2 | 39 |
| 58 | Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 796-805. | 0.8 | 15 |
| 59 | Portable objective assessment of upper extremity motor function in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 61-66. | 1.1 | 4 |
| 60 | Cognitive behavioral therapy for insomnia in Parkinson's disease: a case series. <i>Npj Parkinson's Disease</i> , 2017, 3, 25. | 2.5 | 22 |
| 61 | Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667. | 1.5 | 13 |
| 62 | Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674. | 1.1 | 110 |
| 63 | Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 102-106. | 1.1 | 99 |
| 64 | Corticobasal syndrome. <i>Neurology: Clinical Practice</i> , 2014, 4, 304-312. | 0.8 | 36 |
| 65 | Topographic disorientation following mesial left temporo-occipital hemorrhage. <i>Neurology: Clinical Practice</i> , 2013, 3, 84-85. | 0.8 | 0 |
| 66 | Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleep-related measures. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 208-211. | 1.1 | 91 |
| 67 | Clinical Reasoning: Cerebral cavernous malformations. <i>Neurology</i> , 2009, 73, e44-9. | 1.5 | 9 |
| 68 | Palliative care needs of patients with neurologic or neurosurgical conditions. <i>European Journal of Neurology</i> , 2008, 15, 1265-1272. | 1.7 | 54 |
| 69 | Dementia and depression among nursing home residents in Lebanon: a pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 283-285. | 1.3 | 29 |
| 70 | Du rire aux larmes: Pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine. <i>Epilepsy and Behavior</i> , 2006, 8, 610-615. | 0.9 | 25 |